* indicates required field
Length: 1
Source of Standard: NAACCR
Section Name: Cancer Identification
Record Types: A, M, C, I
XML NAACCR ID: morphCodingSysCurrent
Parent XML Element: Tumor
Required Status:
NPCR Collect: R - Required
CoC Collect: . - No recommendations
SEER Collect: . - No recommendations
CCCR Collect: . - No recommendations
Description:
Code that best describes how morphology is currently coded. If converted, this field shows the system it is converted to. An update or new Morphology Coding System code incorporates all previous coding updates.
Item Data Type:
mixed
Allowable Values
1-9, A, B, C, D, E
Codes:
1 |
ICD-O, First Edition |
|---|---|
2 |
ICD-O, 1986 Field Trial |
3 |
ICD-O, 1988 Field Trial |
4 |
ICD-O, Second Edition |
5 |
ICD-O, Second Edition, plus REAL lymphoma codes effective 1/1/1995 |
6 |
ICD-O, Second Edition, plus FAB codes effective 1/1/1998 |
7 |
ICD-O, Third Edition |
8 |
ICD-O, Third Edition, plus 2008 WHO hematopoietic/lymphoid new terms used for conditions diagnosed 1/1/2010* |
9 |
Other |
A |
ICD-O, Third Edition, plus WHO new terms used for conditions, effective 1/1/2018** |
B |
ICD-O 3.2, effective 1/1/2021 |
C |
ICD-O-3.2, plus, WHO new terms used for conditions, effective 1/1/2022*** |
D |
ICD-O-3.2, plus, WHO new terms used for conditions, effective 1/1/2023*** |
E |
ICD-O-3.2, plus, WHO new terms used for conditions, effective 1/1/2024**** |
Code Notes:
Note:
* These changes were based on the terms of the World Health Organization’s (WHO) fourth edition of the following publications:
- WHO Classification of Hematopoietic and Lymphoid Neoplasms (2007)
- WHO Classification of Tumors of the Central Nervous System (2008)
- WHO Classification of Tumors of the Digestive System (2010)
For details including the list of terms included, refer to the link to the NAACCR ICD-O-3 Implementation Guidelines document, effective for 2014 cases: https://20tqtx36s1la18rvn82wcmpn-wpengine.netdna-ssl.com/wp-content/uploads/2016/11/ICD-O-3-Implementation-Guide-FINAL.pdf.
**These changes are based on the terms of the World Health Organization’s (WHO) fourth edition of the following publications:
- WHO Classification of Tumors of the Breast (2012)
- WHO Classification of Tumors of the Female Reproductive Organs (2013)
- WHO Classification of Tumors of Soft Tissue and Bone (2013)
- WHO Classification of Tumors of the Lung, Pleura, Thymus, and Heart (2015)
- WHO Classification of Tumors of the Urinary System and Male Genital Organs (2016)
- WHO Classifications of Tumors of the Central Nervous System, Revised 4th Ed (2016)
- WHO Classifications of Tumors of the Head and Neck, Revised 4th Edition (2017)
- WHO Classifications of Tumors of Endocrine Organs, Revised 4th Edition (2017)
For details including the list of terms included, refer to the link to the NAACCR ICD-O-3 Implementation Guidelines document, effective for 2018 cases: \<https://20tqtx36s1la18rvn82wcmpn-wpengine.netdna-ssl.com/wp-content/uploads/2018/01/Updated-Jan-10-2018-ICD-O-3-Guidelines-v2.pdf>.
*** These changes are based on the terms of the World Health Organization’s (WHO) fifth edition of the following publications:
- WHO Classification of Breast Tumors (2019)
- WHO Classification of Digestive System Tumors (2019)
- WHO Classification of Female Genital Tumors (2020)
- WHO Classification of Skin and Bone Tumors (2020)
****These changes are based on the terms of the World Health Organization’s (WHO) fifth edition of the following publication:
WHO Classification of Tumors of the Urinary and Male Genital Organs 5th Ed (2022).
For details including the list of terms included, refer to the link to the NAACCR ICD-O-3 Implementation Guidelines document, effective for 2022 cases: TBD.